Fluzone High-Dose - (Seasonal Influenza Vaccine) Forecast and Market Analysis

Description: Fluzone High-Dose - (Seasonal Influenza Vaccine) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluzone High-Dose - (Seasonal Influenza Vaccine) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Fluzone High-Dose is a trivalent, inactivated vaccine designed to have improved efficacy in elderly patients due to the vaccine containing a higher dose of antigen than typical influenza immunizations. The vaccine is manufactured following a very similar methodology to that used to generate Fluzone. Fluzone High-Dose is administered via intramuscular injection, where the viral antigen elicits an immune response that helps protect the patient from subsequent influenza infection. Fluzone High-Dose is manufactured and marketed by Sanofi in the US.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fluzone High-Dose including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fluzone High-Dose from 2012 to 2022.
- Sales information covered for the US.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fluzone High-Dose performance
- Obtain sales forecast for Fluzone High-Dose from 2012 to 2022 in the US.

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Fluzone High-Dose - (Seasonal Influenza Vaccine) Forecast and Market Analysis
- **Web Address:** http://www.researchandmarkets.com/reports/2368621/
- **Office Code:** SC6I5RJ9

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Entrepisewide:</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:**
  - [ ] Mr
  - [ ] Mrs
  - [ ] Dr
  - [ ] Miss
  - [ ] Ms
  - [ ] Prof

- **First Name:**
- **Last Name:**

- **Email Address:** *

- **Job Title:**

- **Organisation:**

- **Address:**

- **City:**

- **Postal / Zip Code:**

- **Country:**

- **Phone Number:**

- **Fax Number:**

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  
Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World